Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on September 28, 2021. The registrant is a Delaware corporation with principal executive offices in South San Francisco, CA, and its common stock trades on Nasdaq under the symbol CBIO.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the receipt of regulatory designation from the U.S. Food and Drug Administration (FDA):
- Orphan Drug Disease Designation (ODD): Granted for the Company's lead product candidate, subcutaneous Marzeptacog alfa (activated) (MarzAA).
- Indication: Treatment of Factor VII Deficiency (FVIID).
- Prior Designations: MarzAA previously received ODD and Fast Track Designation for Hemophilia A/B with inhibitors, and Fast Track Designation for FVIID.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the FDA announcement. It does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard regulatory context of drug development. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the exact scope of the Orphan Drug Designation for MarzAA in the treatment of Factor VII Deficiency via the attached press release (Exhibit 99.1).
- Confirm the current clinical development status of MarzAA for FVIID and Hemophilia A/B with inhibitors.
- Review the Company's most recent 10-Q or 10-K filing for actual financial metrics, as this 8-K contains no financial data.
- Monitor for future filings regarding the impact of this designation on potential market exclusivity or reimbursement strategies.